medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2013, Number 1

<< Back Next >>

Arch Neurocien 2013; 18 (1)

Clinical diagnosis of multiple system atrophy in a number of cases

Sánchez-Jordán A, Martínez-López Y, Marie-Catherine B

Language: Spanish
References: 20
Page: 10-14
PDF size: 320.66 Kb.


ABSTRACT

Multiple systems atrophy (MSA) is a progressive and sporadic neurodegenerative disorder, clinically characterized by parkinsonism, cerebelar ataxia, autonomic dysfunction, and pyramidal signs. The purpose of this work is to evaluate the accuracy in the diagnosis of MSA through the evaluation of clinical criteria. Methods: We examined the history of 21 patients with a diagnosis of MSA according to the International Classification of Diseases (ICD-10), attended at the National Institute of Neurology and Neurosurgery in the last 5 years. They were analyzed by the mean of a simple clinical chart composed by positive and negative criteria, and based on those published by Quinn, the second consensus on MSA and the unified multiple systems atrophy rating scale (UMSARS). Later, the diagnoses were confirmed through the follow up, complementary studies and neuroimage. Results: 8 men and 13 women were analyzed with an average age of 52 years (16 SD). Only 5 patients (24%) fulfilled the probable AMS criteria and in agreement with the diagnostic construct in a 100%. Discussion: AMS is a difficult condition to diagnose due to its clinical features similar to Parkinson’s disease and spinocerebellar ataxia. A thorough evaluation of the autonomic symptomatology is important to perform a differential diagnosis to distinguish AMS from other pathologies. Conclusion: We present here a simple standardized tool for the clinical diagnosis, which resulted highly specific (93.75%) for probable AMS.


REFERENCES

  1. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3: 93-103.

  2. Stephanova N, Bücke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009; 8: 1172-8.

  3. Sung J, Mastri A, Segal E. Pathology of shy-drager syndrome. J Neuropathol Exp Neurol 1979;38:353-68.

  4. Gilman S. Biochemical changes in multiple system atrophy detected with positron emission tomography. Parkinsonism Relat Disord 2001;7:253-6.

  5. Tong J, Wong H, Guttman M, Ang LC, Forno SL, et al. Brain - synuclein accumulation in multiple system atrophy, Parkinson’s disease and progressive supranuclear palsy: a comparative investigation. Brain 2010; 133: 172-88.

  6. Morris HR, Vaughan JR, Datta SR, Bandopadhyay R, Rohan de Silva HA, Schrag A, et al. Multiple system atrophy/progressive supranuclear palsy: -synuclein, synphilin, tau and APOE. Neurology 2000; 55: 1918-20.

  7. Ubhi K, Rockenstein E, Mante M, Patrick C, Adame A, Thukral M, et al. Rifampicin reduces á- synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 2008; 19(13): 1271-6.

  8. Chin SS, Goldman JE. Glial inclussiones in CNS degenerative diseases. J Neuropathol Exp Neurol 1996; 55 (5): 499-508.

  9. Schrag A, Ben- Schlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a crosssectional study. Lancet 1999; 354: 1171-5.

  10. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ. Second consensus statement on the diagnosis of multiple system atrophy. Neurol 2008;71:670-6.

  11. Quinn NP. How to diagnose multiple system atrophy. Mov Disord 2005; 20 (12): S5-S10.

  12. Lee JY, Yun JY, Shin CW, Kim HJ, Jeon BS. Putaminal abnormality on 3-T magnetic resonance imaging in early parkinsonismpredominant multiple system atrophy. J Neurol 2010; 257(12): 2065-70.

  13. Antoni A, Leenders KL, Vontobel P, Maguire RP, Missimer J. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson’s disease. Brain 1997; 120 (Pt 12): 2187-95.

  14. Quinn N, Wenning GK. Multiple system atrophy. Br J Hosp Med 1994;51(9): 492-4.

  15. Wenning GK, Tison F, Seppi K, Sampaio C. Development and validation of the unified multiple system atrophy rating scale (UMSARS). Mov Disord 2004; 19(12):1391-402.

  16. Gilman S, Low PA, Quinn N. Consensus statement on the diagnosis of multiple systems atrophy. J Neurol Sci 1999; 163(1): 94-8.

  17. Jellinger K. New developments in the pathology of Parkinson’s disease. In: Streifler MB, Korczyn AD, Melamed E, Youdium MBH, eds. Advances in neurology Vol 53. Parkinson’s disease. Anatomy, pathology, and therapy. New York: Raven Press, 1990: 1-16.

  18. Lees AJ. The treatment of multiple system atrophy: striatonigral degeneration and olivopontocerebellar degeneration. In: Bannister R, ed. Autonomic failure: a textbook of clinical disorders of the autonomic nervous system, 2nd ed. Oxford: Oxford University Press, 1988: 596-604.

  19. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinsons disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55(3):181-4.

  20. Lipp A, Sandroni P, Ahlskog E, Fealey RD, Kimpinski K. Prospective differentiation of multiple system atrophy from Parkinson’s disease, with and without autonomic failure. Arch Neurol 2009; 66(6): 742-50.




2020     |     www.medigraphic.com